Surisham Dhillon
Newhall, CANPI 1770652299
Payments from drug & device makers
$103,960in general payments, 2019–2025
Across 191 payments — averaging $544.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$37K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$26K
- Pfizer$19K
- Eli Lilly$15K
- Janssen Research & Development, LLC$5K
- AbbVie$571
- plus $2K from 29 others
What the payments were for
- Food & beverage$2,608100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
19
20
21
22
23
24
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 23 | $36,864 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $25,975 |
| Pfizer | 2 | $18,788 |
| Eli Lilly | 1 | $15,112 |
| Janssen Research & Development, LLC | 7 | $4,613 |
| AbbVie(2 entities) | 29 | $571 |
| Supernus Pharmaceuticals, Inc. | 28 | $235 |
| UCB, Inc. | 10 | $192 |
| Sanofi | 12 | $158 |
| Avanir Pharmaceuticals, Inc. | 11 | $126 |
| Livanova USA, Inc. | 6 | $116 |
| Amgen | 6 | $114 |
| Genentech USA, Inc. | 6 | $106 |
| EMD Serono, Inc. | 4 | $95 |
| Assertio Therapeutics, Inc. | 4 | $81 |
| Teva Pharmaceuticals USA, Inc. | 4 | $75 |
| Greenwich Biosciences, Inc. | 2 | $72 |
| Lilly USA, LLC | 3 | $67 |
| Kyowa Kirin, Inc. | 3 | $65 |
| Argenx US, Inc. | 2 | $56 |
| Biohaven Pharmaceuticals, Inc. | 3 | $51 |
| Biogen | 3 | $49 |
| AstraZeneca | 3 | $43 |
| Akcea Therapeutics, Inc. | 2 | $43 |
| Adamas Pharmaceuticals, Inc. | 2 | $41 |
| Merz North America, Inc. | 1 | $39 |
| Amneal Pharmaceuticals LLC | 1 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $26 |
| Novartis | 1 | $25 |
| Zyla Life Sciences, Inc. | 2 | $25 |
| Acadia Pharmaceuticals Inc | 2 | $23 |
| Eisai Inc. | 1 | $23 |
| GSK | 1 | $19 |
| CSL Behring | 1 | $18 |
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.